Enzyme-linked immunosorbent assay for measurement of cytomegalovirus glycoprotein B antibody in serum.

Measurement of antibody to cytomegalovirus (CMV) glycoprotein B (gB) is valuable in the assessment of the antibody response to infection and to gB-containing vaccines. For this purpose, an enzyme-linked immunosorbent assay (ELISA) with a recombinant CMV gB molecule as the antigen was evaluated. Sera from 168 anti-CMV IgG-positive and 100 seronegative subjects were used to evaluate the anti-gB antibody assay.

Vaccine prevention of maternal cytomegalovirus infection.

Background: Congenital infection with cytomegalovirus (CMV) is an important cause of hearing, cognitive, and motor impairments in newborns.

Methods: In this phase 2, placebo-controlled, randomized, double-blind trial, we evaluated a vaccine consisting of recombinant CMV envelope glycoprotein B with MF59 adjuvant, as compared with placebo. Three doses of the CMV vaccine or placebo were given at 0, 1, and 6 months to CMV-seronegative women within 1 year after they had given birth.

Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding.

Background: An antibody method based on absorption of serum with cytomegalovirus (CMV) glycoprotein B (gB) was developed for detection of infection during clinical trials of CMV gB vaccine. Previous study showed that this method detected the antibody response to infection and was negative with vaccine induced immunity.

Objectives: In an ongoing efficacy trial of CMV gB vaccine the ability of the gB-absorbed CMV IgG assay to detect CMV infection was assessed and compared with viral culture results.

Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine.

Preabsorption of sera with cytomegalovirus (CMV) glycoprotein B (gB) prior to testing for CMV IgG antibody was evaluated for detection of CMV infection during CMV gB vaccine clinical trials. Although, 98.2% of 109 CMV gB vaccine recipients were seropositive with a standard assay, preabsorption of sera with gB reduced their CMV antibody to extremely low levels compared with subjects with CMV infection.